SAN FRANCISCO – Boston Scientific Corp. said its bid to bring its Lotus Edge transcatheter aortic valve technology (TAVR) to the U.S. will continue as planned. During a Tuesday breakout session at the 35th annual J.P. Morgan Healthcare conference, the company said the issue had been resolved. Boston Scientific also noted it wasn't a design flaw in the device nor were there any safety issues. The firm said a fix to Lotus Edge required a combination of "minor process and specification changes", rather than any meaningful, costly and lengthy product redesigns. Read More
